Immunohistochemical analyses of sporadic and familial (185delAG carriers) ovarian cancer in Israel

European Journal of Cancer

Volumn 36, Issue 9, 2000, Pages 1120-1124

  Ravid, A ^a   Barschack, I ^b   Hirsh Yechezkel, G ^b   Goldberg, I ^b   Bar Sade, R B ^c   Chetrit, A ^b   Reder, I ^b   Ben Baruch, G ^b   Gotlieb, W H ^b   Koplovic, J ^b   Friedman, E ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

Author keywords

BRCA1; BRCA2; Inherited predisposition; Ovarian cancer; p53; Prognostic factors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISRAEL; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; STAINING;

AGED; BRCA2 PROTEIN; FEMALE; GENES, BRCA1; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; JEWS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEDIGREE; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 19244374175     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00096-4     Document Type: Article

References (43)

1. Daly MB. The epidemiology of ovarian cancer. In Osols RF, ed. Hematol/Oncol Clinics of North America 1992, 729-738.
2. Cancer Incidence in Five Continents. Vol V. Lyon, 1987.
3. Israel Cancer Registry. Cancer in Israel: facts and figures. 1990-1994. Jerusalem, 1998.
4. Wingo P.A., Tong T., Bolden S. Cancer statistics 1995. CA Cancer J. Clin. 45:1995;8-30.
5. Szabo C.I., King M.C. Inherited breast and ovarian cancer. Hum. Mol. Genet. 4:1995;1811-1817.
6. Gallion H.H., Pieretti M., DePrriest P.D., van Nagell J.R. Jr. The molecular basis of ovarian cancer. Cancer. 76(10 Suppl.):1995;1992-1997.
7. Modan B., Gak E., Hirsh G.et al. High frequency of the 185delAG mutation in ovarian cancer in Israel. JAMA. 276:1996;1823-1825.
8. Abeliovich D., Kaduri L., Lerer I.et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer patients among Ashkenazi women. Am. J. Hum. Genet. 60:1997;505-514.
9. Streuwing J.P., Abeliovitch D., Peretz T.et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat. Genet. 11:1995;198-200.
10. Bar-Sade R.B., Theodor L., Gak L.et al. Could the 186delAG BRCA1 mutation be an ancient Jewish mutation? Eur. J. Hum. Genet. 5:1997;413-416.
11. Bar-Sade R.B., Kruglikova A., Modan B.et al. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to ashkenazim. Hum. Mol. Genet. 7:1998;801-805.
12. Rubin S.C., Benjamin I., Bahbakht K.et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Eng. J. Med. 335:1996;1413-1416.
13. Aida H., Takakuwa K., Nagata H.et al. Clinical features of ovarian cancer in Japanese women with germline mutations of BRCA1. Clin. Cancer Res. 4:1998;235-240.
14. Johannsson O.T., Ranstam J., Borg A., Olsson H. Survival of BRCA1 breast and ovarian cancer patients. a population-based study from southern Sweden J. Clin. Oncol. 16:1998;397-404.
15. Johannsson O.T., Idvall I., Anderson C.et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer. 33:1997;362-371.
16. Eisinger F., Stoppa-Lyonnet D., Longy M.et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 56:1997;471-474.
17. Eisinger F., Jacquemier J., Guinebretiere J.M., Birnbaum D., Sobol H. P53 involvement in BRCA1 associated breast cancer. Lancet. 35:1997;1101.
18. Eisinger F., Nogues C., Birnbaum D., Jacquemier J., Sobol H.et al. Low frequency of lymph-node metastasis in BRCA1-associated breast cancer. Lancet. 351:1998;1633-1634.
19. Pathology of familial breast cancer. differences between cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases Lancet. 349:1997;1505-1510.
20. Verhoog L.C., Brekelmans C.T., Seynaeve C.et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 351:1998;316-321.
21. Rhei E., Bogomolniy F., Federici M.G.et al. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res. 58:1998;3193-3196.
22. Marks J.R., Davidoff A.M., Kerns B.J.et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 51:1991;2979-2984.
23. Hartmann L.C., Podratz K.C., Keeney G.L.et al. Prognostic significance of p53 immuno-staining in epithelial ovarian cancer. J. Clin. Oncol. 12:1994;64-69.
24. Eccles D.M., Brett L., Lessells A.et al. Overexpression of p53 protein and allele loss at 17p13 in ovarian carcinoma. Br. J. Cancer. 65:1992;40-44.
25. Kohler M.F., Marks J.R., Wiseman R.W.et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl. Cancer Inst. 85:1993;1513-1519.
26. Jacquemier J., Moles J.P., Penault-Llorca F.et al. P53 immunohistochemical analysis in breast cancer with four monoclonal antibodies. comparison of staining and PCR-SSCP results Br. J. Cancer. 69:1994;846-852.
27. Kappes S., Milde-Langosch K., Kressin P.et al. P53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int. J. Cancer. 64:1995;52-59.
28. Casey G., Lopez M.E., Ramos J.C.et al. DNA sequence analysis of exons 2 through 11 and immunohistochemiccal staining are required to detect all known p53 alternations in human malignancies. Oncogene. 13:1996;1971-1981.
29. Henriksen R., Strang P., Wilander E., Backstrom T., Tribukait B., Oberg K. P53 expression in epithelial ovarina neoplasms. relationship to clinical and pathological paramters, Ki-67 expression and flow cytometry Gynecol. Oncol. 53:1994;301-306.
30. Geisler J.P., Geisler H.E., Wiemann M.C., Givens S.S., Zhou Z., Miller G.A. Quantification of p53 in epithelial ovrian cancer. Gynecol. Oncol. 66:1997;435-438.
31. Viale G., Maisonneuve P., Bonoldi E.et al. The combined evaluation of p53 accumulation and of Ki-67 (mIB1) labelling index provides independent information on overall survival of ovaarian carcinoma patients. Ann. Oncol. 8:1997;469-476.
32. Buttitta F., Marchetti A., Gadducci A.et al. P53 alterations are predictive of chemoresistance and aggerssiveness in ovarian carcinomas. a molecular and immunohistochemical study Br. J. Cancer. 75:1997;230-235.
33. Ioakim-Liossi A., Karakitsos P., Aroni K.et al. p53 protein expression and DNA ploidity in common epithelial tumors of the expression and DNA ploidity in common epithelial tumors of the ovary. Acta Cytol. 41:1997;1714-1718.
34. International Federation of Genaecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynaecol Scand, 1971, 50, 1-7.
35. Serov S.F., Scully R.E., Sobin L.H. International histological classification of tumors No. 9. Histological typing of ovarian tumors. 1973;World Health Organisation, Geneva.
36. Fisher C.J., Gillett C.E., Vojtesek B., Barnes D.M., Millis R.R. Problems with p53 immunohistochemical staining. the effect of fixation and variation in the methods of evaluation Br. J. Cancer. 69:1994;26-31.
37. Renninson J., Baker B.W., McGown A.T.et al. Immunohistochemical detection of mutant p53 protin in epithelial ovarian cancer using polyclonal antibody CM1. correlation with histopathology and clincal features Br. J. Cancer. 69:1994;609-612.
38. Giorno R. A comparison of two immunoperoxidase staining methods bases on the avidin-biotin interaction. Diagn. Immunol. 2:1984;161-166.
39. Guesdon J.L., Ternynck T., Avrameas S. The use of Avidin-biotin interaction in immunoenzymatic techniques. J. Histochem. Cytochem. 27:1979;1131-1139.
40. Diebold J., Deisenhofer I., Baretton G.B.et al. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential. comparison with serous cystadenomas and invasive serous carcinomas Lab. Invest. 75:1996;473-485.
41. Sobol H., Stoppa-Lyonnet D., Bressac-de-Paillerets B.et al. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res. 56:1996;3216-3219.
42. Ramus S.J., Bobrow L.G, . Pharoah P.D.et al. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer. 25:1999;91-96.
43. Teneriello M.G., Ebina M., Linnoila R.I.et al. P53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53:1993;3103-3108.